[go: up one dir, main page]

NO20083891L - Anti-5T4 antistoffer og anvendelser derav - Google Patents

Anti-5T4 antistoffer og anvendelser derav

Info

Publication number
NO20083891L
NO20083891L NO20083891A NO20083891A NO20083891L NO 20083891 L NO20083891 L NO 20083891L NO 20083891 A NO20083891 A NO 20083891A NO 20083891 A NO20083891 A NO 20083891A NO 20083891 L NO20083891 L NO 20083891L
Authority
NO
Norway
Prior art keywords
antibodies
antibody
preparation
methods
drug conjugates
Prior art date
Application number
NO20083891A
Other languages
English (en)
Inventor
Arthur Kunz
Nitin Krishnaji Damle
Erwin Raymond Arsene Boghaert
Kimberly Ann Marquette
Philip Ross Hamann
Kiran Khandke
Kodangattil Sreekumar
Lioudmila Tchistiakova
Davinder Gill
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38445207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083891(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20083891L publication Critical patent/NO20083891L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anti-5T4-antistoffer, anti-5T4 antistofif/medikament-konjugater og metoder for fremstilling og anvendelse av samme.
NO20083891A 2006-03-10 2008-09-11 Anti-5T4 antistoffer og anvendelser derav NO20083891L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78134606P 2006-03-10 2006-03-10
US89124807P 2007-02-23 2007-02-23
PCT/US2007/063685 WO2007106744A2 (en) 2006-03-10 2007-03-09 Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NO20083891L true NO20083891L (no) 2008-12-03

Family

ID=38445207

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083891A NO20083891L (no) 2006-03-10 2008-09-11 Anti-5T4 antistoffer og anvendelser derav

Country Status (29)

Country Link
US (5) US8044178B2 (no)
EP (3) EP2368914B1 (no)
JP (1) JP5523824B2 (no)
KR (2) KR101443752B1 (no)
CN (1) CN101437850B (no)
AR (1) AR059809A1 (no)
AU (1) AU2007226696C1 (no)
BR (1) BRPI0708771B8 (no)
CA (1) CA2645097C (no)
CR (1) CR10273A (no)
DK (2) DK1994055T3 (no)
EC (1) ECSP088733A (no)
ES (2) ES2498517T3 (no)
GT (1) GT200800181A (no)
IL (2) IL193986A (no)
MX (1) MX2008011492A (no)
MY (1) MY148763A (no)
NO (1) NO20083891L (no)
NZ (2) NZ596295A (no)
PA (1) PA8718601A1 (no)
PE (1) PE20080119A1 (no)
PL (1) PL1994055T3 (no)
PT (1) PT1994055E (no)
SA (1) SA07280101B1 (no)
SG (1) SG170091A1 (no)
SI (1) SI1994055T1 (no)
TW (2) TWI409277B (no)
WO (1) WO2007106744A2 (no)
ZA (1) ZA200808075B (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978985A2 (en) * 2005-12-23 2008-10-15 Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting hdgf
AR059809A1 (es) 2006-03-10 2008-04-30 Wyeth Corp Anticuerpos anti-5t4 y sus usos
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
JP5788863B2 (ja) 2009-03-27 2015-10-07 ワイス・エルエルシー 腫瘍開始細胞およびその使用方法
GB0918383D0 (en) * 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
US9592331B2 (en) 2011-02-07 2017-03-14 Aggamin Llc Methods and systems for treating eclampsia or pre-eclampsia
KR101529810B1 (ko) 2011-04-01 2015-06-26 와이어쓰 엘엘씨 항체-약물 접합체
JP6281163B2 (ja) * 2011-08-22 2018-02-21 エメルゲント バイオソリューションズ カナダ クロストリジウム・ディフィシレ抗体
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
MX361058B (es) 2012-01-24 2018-11-23 Pfizer Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
AU2013359167B2 (en) 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
WO2014137931A1 (en) * 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
CA2915960A1 (en) * 2013-06-17 2014-12-24 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
ES2726850T3 (es) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco
ES2754397T3 (es) 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
DK3151865T3 (da) 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
SG11201609912TA (en) 2014-05-29 2016-12-29 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
BR112017001821A2 (pt) 2014-07-29 2017-11-21 Cellectis receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer
EP3194432B1 (en) 2014-07-31 2019-04-10 Cellectis Ror1 specific multi-chain chimeric antigen receptor
EP3189073B2 (en) 2014-09-04 2025-06-11 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
HK1247132A1 (zh) * 2015-01-22 2018-09-21 Prothena Biosciences Limited 识别medin的抗体
EP3298046B1 (en) 2015-05-20 2025-02-12 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
BR112018005322A2 (pt) 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
PL3380122T3 (pl) * 2015-11-24 2021-12-13 Byondis B.V. Przeciwciała anty-5T4 i koniugaty przeciwciało-lek
JP2019508023A (ja) * 2015-12-24 2019-03-28 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド Ｔｐｂｇ抗体およびその調製方法、その共役体並び用途
SG11201900464TA (en) * 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
CN108084265B (zh) * 2016-11-23 2021-07-02 复旦大学 特异性结合人的5t4抗原的全人源单域抗体及其应用
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
US11427645B2 (en) 2017-03-15 2022-08-30 Oxford Biomedica (Uk) Limited 5T4-targeting agents and methods
EP3608335A4 (en) * 2017-04-05 2020-04-29 XDCExplorer (Shanghai) Co., Ltd. HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
EP3634476A4 (en) * 2017-06-06 2021-06-02 The Regents of The University of California HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF
NZ761636A (en) 2017-07-20 2023-07-28 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
CN112135904A (zh) 2018-01-03 2020-12-25 帕利昂制药有限公司 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法
AU2019233523B2 (en) 2018-03-12 2026-01-08 Genmab A/S Antibodies
JP7724061B2 (ja) 2018-04-11 2025-08-15 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
EA202191175A1 (ru) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
US20230257479A1 (en) 2019-09-12 2023-08-17 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
BR112022014667A2 (pt) 2020-01-29 2022-09-20 Inhibrx Inc Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
CN115279403A (zh) 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
US20220288244A1 (en) * 2020-10-22 2022-09-15 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
EP4232052A4 (en) * 2020-10-22 2025-08-20 Actinium Pharmaceuticals Inc COMBINATION OF RADIOMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
US20220251239A1 (en) * 2020-10-22 2022-08-11 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
MX2023008028A (es) * 2021-01-06 2023-08-14 Palleon Pharmaceuticals Inc Anticuerpos anti-pd-l1 y proteinas de fusion de estos.
KR20250004629A (ko) * 2022-02-21 2025-01-08 컨셉트 투 메디신 바이오테크 컴패니 리미티드 항-5t4 항체 및 그것의 용도
TW202421207A (zh) 2022-09-30 2024-06-01 大陸商上海迪諾醫藥科技有限公司 苯并氮雜卓衍生物、含其的偶聯物及其應用
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
CN116715773B (zh) * 2023-02-28 2024-03-01 星奕昂(上海)生物科技有限公司 一种靶向5t4的抗体及其应用
CN120882755A (zh) * 2023-03-08 2025-10-31 百奥赛图(北京)医药科技股份有限公司 抗5t4抗体及其用途
AR132178A1 (es) * 2023-03-22 2025-06-04 Salubris Biotherapeutics Inc Dominios de unión al antígeno anti-5t4, conjugados anticuerpo-fármaco, y métodos de uso de los mismos
CN121002067A (zh) * 2023-04-03 2025-11-21 非同（成都）生物科技有限公司 抗5t4抗体及其应用
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
EP0336562B1 (en) 1988-03-04 1995-06-14 Cancer Research Campaign Technology Ltd. Improvements relating to antigens
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
ES2332435T3 (es) 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited Vector dirigido a tumores.
EP2042598A1 (en) 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1130094A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
WO2002038612A2 (en) * 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
CA2445898A1 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2006004950A2 (en) 2004-06-30 2006-01-12 International Bioimmune Systems, Inc. Humanized monoclonal antibody 31.1 as an anticancer agent
CN101035564A (zh) 2004-09-10 2007-09-12 惠氏公司 人源化的抗5t4抗体和抗5t4抗体/加利车霉素缀合物
US20090285806A1 (en) * 2004-10-05 2009-11-19 Martin Sinacore Methods and compositions for improving recombinant protein production
AR059809A1 (es) 2006-03-10 2008-04-30 Wyeth Corp Anticuerpos anti-5t4 y sus usos
EP3056203B1 (en) 2010-04-21 2017-12-13 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
KR101529810B1 (ko) 2011-04-01 2015-06-26 와이어쓰 엘엘씨 항체-약물 접합체

Also Published As

Publication number Publication date
IL240245A (en) 2017-05-29
SI1994055T1 (sl) 2014-08-29
GT200800181A (es) 2010-05-25
PA8718601A1 (es) 2009-05-15
NZ596295A (en) 2013-01-25
DK1994055T3 (da) 2014-08-25
KR101264216B1 (ko) 2013-05-31
DK2368914T3 (en) 2019-03-04
AU2007226696B2 (en) 2013-08-29
CA2645097C (en) 2019-09-17
TW201335189A (zh) 2013-09-01
US20160185859A1 (en) 2016-06-30
IL193986A0 (en) 2011-08-01
EP2368914B1 (en) 2019-01-02
JP2009529578A (ja) 2009-08-20
HK1121473A1 (en) 2009-04-24
MX2008011492A (es) 2008-09-22
BRPI0708771B8 (pt) 2021-05-25
SG170091A1 (en) 2011-04-29
US20070231333A1 (en) 2007-10-04
PT1994055E (pt) 2014-09-15
AU2007226696C1 (en) 2016-02-04
EP3539989A1 (en) 2019-09-18
BRPI0708771B1 (pt) 2019-10-22
PE20080119A1 (es) 2008-03-04
US8044178B2 (en) 2011-10-25
CN101437850B (zh) 2013-10-09
US20120064600A1 (en) 2012-03-15
US8759495B2 (en) 2014-06-24
ES2712942T3 (es) 2019-05-16
IL240245A0 (en) 2015-09-24
TW200804424A (en) 2008-01-16
US9902771B2 (en) 2018-02-27
JP5523824B2 (ja) 2014-06-18
WO2007106744A8 (en) 2008-10-02
ZA200808075B (en) 2012-03-28
RU2008137074A (ru) 2010-04-20
WO2007106744A2 (en) 2007-09-20
WO2007106744A3 (en) 2007-11-29
TWI409277B (zh) 2013-09-21
ES2498517T3 (es) 2014-09-24
CA2645097A1 (en) 2007-09-20
KR101443752B1 (ko) 2014-09-26
TWI421257B (zh) 2014-01-01
EP1994055B1 (en) 2014-07-02
AR059809A1 (es) 2008-04-30
ECSP088733A (es) 2008-10-31
NZ571208A (en) 2011-12-22
CR10273A (es) 2008-11-26
EP1994055A2 (en) 2008-11-26
US20180162937A1 (en) 2018-06-14
SA07280101B1 (ar) 2011-10-03
IL193986A (en) 2015-08-31
KR20130018980A (ko) 2013-02-25
CN101437850A (zh) 2009-05-20
PL1994055T3 (pl) 2015-02-27
KR20080106345A (ko) 2008-12-04
EP2368914A1 (en) 2011-09-28
AU2007226696A1 (en) 2007-09-20
US20140308302A1 (en) 2014-10-16
MY148763A (en) 2013-05-31
BRPI0708771A2 (pt) 2011-06-14

Similar Documents

Publication Publication Date Title
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
HUS2300026I1 (hu) Anti-CTLA-4 ellenanyag készítmények
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
NO20084356L (no) Anti TAT226-antistoffer og immunokonjugater
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
BRPI0818780A2 (pt) Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
DK2176296T3 (da) Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
DK2158217T3 (da) Humant monoklonalt antistof, der neutraliserer vaskulær endotel vækstfaktorreceptor, og anvendelse heraf
EP2233501A4 (en) HUMANIZED MONOCLONAL ANTI-CD34 ANTIBODIES AND THEIR PREPARATION AND APPLICATIONS
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
NO20090333L (no) Fremgangsmater og preparater rettet mot hepsin
DK1899377T3 (da) Humaniserede antistoffer, der er specifikke for NOGO-A, og farmaceutiske anvendelser deraf.
TR201902670T4 (tr) Anti-5t4 antikorları ve bunların kullanımları.
HK1157363A1 (zh) 抗伸展的一型鞘糖脂抗体、其衍生物及用途
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application